Who are Comparison of Risperidone and Aripiprazole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Phase 3B: Clozapine or another SGAs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comparison-of-risperidone-and-aripiprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Comparison of Risperidone and Aripiprazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Risperidone and Aripiprazole (Comparison of Risperidone and Aripiprazole) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Second-generation antipsychotic (atypical antipsychotic). Area: Psychiatry / Neurology.

marketed Second-generation antipsychotic (atypical antipsychotic) Dopamine D2 receptor (risperidone: antagonist; aripiprazole: partial agonist); serotonin 5-HT2A receptor (risperidone) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Comparison of Risperidone and Aripiprazole (Comparison of Risperidone and Aripiprazole) — Vanderbilt University Medical Center. This is a comparative analysis of two marketed antipsychotics with different mechanisms: risperidone blocks dopamine D2 and serotonin 5-HT2A receptors, while aripiprazole acts as a dopamine D2 partial agonist.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparison of Risperidone and Aripiprazole TARGET	Comparison of Risperidone and Aripiprazole	Vanderbilt University Medical Center	marketed	Second-generation antipsychotic (atypical antipsychotic)	Dopamine D2 receptor (risperidone: antagonist; aripiprazole: partial agonist); serotonin 5-HT2A receptor (risperidone)
Phase 3B: Clozapine or another SGAs	Phase 3B: Clozapine or another SGAs	Shanghai Mental Health Center	phase 3	Second-generation antipsychotic (atypical antipsychotic)	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Second-generation antipsychotic (atypical antipsychotic) class)

Shanghai Mental Health Center · 1 drug in this class
Vanderbilt University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparison of Risperidone and Aripiprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/comparison-of-risperidone-and-aripiprazole. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab